Despite Ranbaxy Setback, Indian Cos' Drug Research Stays on Course (India)
This article was originally published in PharmAsia News
The malaria drug industry faced a major setback following the withdrawal of funding by the Medicines for Malaria Venture (MMV) from an attempt by Ranbaxy Ltd. to develop a new antimalarial treatment. Although Ranbaxy plans to go forward, without funding some are skeptical of the drug's chances. However, two other Indian companies also have promising antimalarial drugs in development. Ipca Laboratories Ltd. leads the pack with four prospects. Two of these molecules are being developed with the support of the Central Drug Research Institute and are currently in preclinical or phase I trials. A third molecule, developed by the Indian Institute of Science, is also in preclinical trials. Ipca's fourth drug in the works is just a new dosage of an older treatment. The fifth drug is being tested by Unimark Pharma Ltd. with the support of the MMV. All five drugs are based on some combination of arteminsinin, a Chinese herb. (Click here for more
You may also be interested in...
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.
A proposed rule released last month by the US Department of Health and Human Services is the Trump administration’s “latest attempt to sabotage HHS programs,” wrote Jessica Schubel, a senior policy analyst for the Center on Budget and Policy Priorities. See what the policy expert said about it in her blog post here.
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.